Investor Alert: Dr. Reddy's Laboratories Faces Securities Fraud Investigation
Pomerantz Law Firm is investigating potential securities fraud or other unlawful business practices by Dr. Reddy's Laboratories Limited (NYSE: RDY) and its officers or directors on behalf of investors. The investigation follows a July 2026 earnings report that revealed significant financial setbacks due to issues with semaglutide batches, which led to a ₹2.4 billion provision. On the news, Dr. Reddy's stock price dropped by $1.18 per share (9.4%) on July 22, closing at $11.38. The firm is inviting investors who may have been affected to contact its legal team for potential inclusion in a class action lawsuit. Pomerantz LLP has long been recognized as one of the leading firms in corporate and securities litigation, with a history spanning over eight decades under the leadership of founder Abraham L. Pomerantz.
Tickers: $RDY
Topics: earnings_discrepancy investor_protection securities_law